Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Share-based Compensation: 2021-2024

Historic Share-based Compensation for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $33.0 million.

  • Amylyx Pharmaceuticals' Share-based Compensation rose 4.01% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 21.86%. This contributed to the annual value of $33.0 million for FY2024, which is 11.09% down from last year.
  • Amylyx Pharmaceuticals' Share-based Compensation amounted to $33.0 million in FY2024, which was down 11.09% from $37.2 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Share-based Compensation's 5-year high stood at $37.2 million during FY2023, with a 5-year trough of $3.1 million in FY2021.
  • Its 3-year average for Share-based Compensation is $30.6 million, with a median of $33.0 million in 2024.
  • Its Share-based Compensation has fluctuated over the past 5 years, first spiked by 592.41% in 2022, then declined by 11.09% in 2024.
  • Amylyx Pharmaceuticals' Share-based Compensation (Yearly) stood at $3.1 million in 2021, then spiked by 592.41% to $21.7 million in 2022, then soared by 71.14% to $37.2 million in 2023, then dropped by 11.09% to $33.0 million in 2024.